News
Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors
Garner’s pharma development expertise includes women’s health and gynecologic oncology COLUMBUS,...
Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020
The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 03, 2020...
Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020
The poster will be made available at SABCS.org on Wednesday, Dec. 9 COLUMBUS, Ohio, Dec. 02, 2020...
Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib
Working with Tempus to identify and enroll trial participants, study will evaluate safety of...
Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada
Study of lasofoxifene versus fulvestrant in patients with metastatic breast cancer will include...
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
The multicenter Phase 2 trial, Sermonix’s Evaluation of Lasofoxifene and Abemaciclib in ESR1...
Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting
University of Chicago preclinical study compared combination to that of fulvestrant and...
Sermonix to Co-sponsor ‘Candid Conversations’ Patient Advocacy Panel With Breastcancer.org at San Antonio Breast Cancer Symposium
Discussion will examine sexual health and intimacy, bone health, joint and muscle pain, and...
Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Biopharmaceutical company is partnering with Sysmex Inostics to identify appropriate study...
To sign up for future Sermonix press releases, please enter your information below.